Several CLPP agonists (ONC201, as well as other imipridones) were demonstrated to be quite efficient against not only bulk tumor cells but also cancer stem cells, cancer-associated fibroblasts, and immune cells within the tumor microenvironment. The gene discussed is CLPP; the disease is cancer.